Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2017, Article ID 5490963, 8 pages
https://doi.org/10.1155/2017/5490963
Research Article

Assessing the Association between Serum Ferritin, Transferrin Saturation, and C-Reactive Protein in Northern Territory Indigenous Australian Patients with High Serum Ferritin on Maintenance Haemodialysis

1Royal Darwin Hospital, Department of Nephrology, Division of Medicine, Tiwi, Darwin, NT, Australia
2Northern Territory Medical Programme, Flinders University School of Medicine, Tiwi, Darwin, NT, Australia
3Wellbeing and Preventable Chronic Disease Division, Menzies School of Health Research, Charles Darwin University, Casuarina, NT, Australia

Correspondence should be addressed to Sandawana William Majoni; moc.loa@wanawadnas

Received 8 October 2016; Revised 29 December 2016; Accepted 9 January 2017; Published 24 January 2017

Academic Editor: Jaime Uribarri

Copyright © 2017 Sandawana William Majoni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Locatelli, P. Bárány, A. Covic et al., “Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement,” Nephrology Dialysis Transplantation, vol. 28, no. 6, pp. 1346–1359, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. B. Wish, “Assessing iron status: beyond serum ferritin and transferrin saturation,” Clinical Journal of the American Society of Nephrology, vol. 1, supplement 1, pp. S4–S8, 2006. View at Publisher · View at Google Scholar · View at Scopus
  3. F. J. Baillie, A. E. Morrison, and I. Fergus, “Soluble transferrin receptor: a discriminating assay for iron deficiency,” Clinical and Laboratory Haematology, vol. 25, no. 6, pp. 353–357, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Berlin, A. Meyer, P. Rotman-Pikielny, A. Natur, and Y. Levy, “Soluble transferrin receptor as a diagnostic laboratory test for detection of iron deficiency anemia in acute illness of hospitalized patients,” Israel Medical Association Journal, vol. 13, no. 2, pp. 96–98, 2011. View at Google Scholar · View at Scopus
  5. R. MacGinley, R. Walker, and M. Irving, “KHA-CARI guideline: use of iron in chronic kidney disease patients,” Nephrology, vol. 18, no. 12, pp. 747–749, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. E. Gaweda, P. Bhat, G. A. Maglinte et al., “TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients,” Hemodialysis International, vol. 18, no. 1, pp. 38–46, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. S. W. Majoni, J.-A. Ellis, H. Hall, A. Abeyaratne, and P. D. Lawton, “Inflammation, high ferritin, and erythropoietin resistance in indigenous maintenance hemodialysis patients from the Top End of Northern Australia,” Hemodialysis International, vol. 18, no. 4, pp. 740–750, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. L. E. K. Ratcliffe, W. Thomas, J. Glen et al., “Diagnosis and management of iron deficiency in CKD: a summary of the NICE guideline recommendations and their rationale,” American Journal of Kidney Diseases, vol. 67, no. 4, pp. 548–558, 2016. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Rabe-Hesketh and A. Skrondal, Multilevel and Longitudinal Modeling Using Stata, Volumes I and II, Third Edition: Multilevel and Longitudinal Modeling Using Stata, Volume II ... Counts, and Survival, Third Edition, Stata Press, 2012.
  10. A. Karaboyas, J. Zee, H. Morgenstern et al., “Understanding the recent increase in ferritin levels in united states dialysis patients: Potential impact of changes in intravenous iron and erythropoiesis-stimulating agent dosing,” Clinical Journal of the American Society of Nephrology, vol. 10, no. 10, pp. 1814–1821, 2015. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Vanholder and S. Ringoir, “Infectious morbidity and defects of phagocytic function in end-stage renal disease: a review,” Journal of the American Society of Nephrology, vol. 3, no. 9, pp. 1541–1554, 1993. View at Google Scholar · View at Scopus
  12. R. M. S. Chalmers, S. W. Majoni, L. Ward, G. J. Perry, Z. Jabbar, and B. J. Currie, “Melioidosis and end-stage renal disease in tropical northern Australia,” Kidney International, vol. 86, no. 5, pp. 867–870, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. B. J. Stewart, T. Gardiner, G. J. Perry, and S. Y. C. Tong, “Reduction in Staphylococcus aureus bacteraemia rates in patients receiving haemodialysis following alteration of skin antisepsis procedures,” Journal of Hospital Infection, vol. 92, no. 2, pp. 191–193, 2016. View at Publisher · View at Google Scholar · View at Scopus
  14. P. M. Ridker, C. H. Hennekens, J. E. Buring, and N. Rifai, “C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women,” New England Journal of Medicine, vol. 342, no. 12, pp. 836–843, 2000. View at Publisher · View at Google Scholar · View at Scopus
  15. D. W. Coyne, T. Kapoian, W. Suki et al., “Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) study,” Journal of the American Society of Nephrology, vol. 18, no. 3, pp. 975–984, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. T. Kapoian, N. B. O'Mara, A. K. Singh et al., “Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin,” Journal of the American Society of Nephrology, vol. 19, no. 2, pp. 372–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. D. W. Coyne, “Hepcidin: clinical utility as a diagnostic tool and therapeutic target,” Kidney International, vol. 80, no. 3, pp. 240–244, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. S. Larson and D. W. Coyne, “Understanding and exploiting hepcidin as an indicator of anemia due to chronic kidney disease,” Kidney Research and Clinical Practice, vol. 32, no. 1, pp. 11–15, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Rossi, “Hepcidin-the iron regulatory hormone,” The Clinical biochemist. Reviews, vol. 26, no. 3, pp. 47–49, 2005. View at Google Scholar
  20. C.-Y. Wang and J. L. Babitt, “Hepcidin regulation in the anemia of inflammation,” Current Opinion in Hematology, vol. 23, no. 3, pp. 189–197, 2016. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Weiss, “Anemia of chronic disorders: new diagnostic tools and new treatment strategies,” Seminars in Hematology, vol. 52, no. 4, pp. 313–320, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. B. Ritchie, Y. McNeil, and D. R. Brewster, “Soluble transferrin receptor in Aboriginal children with a high prevalence of iron deficiency and infection,” Tropical Medicine and International Health, vol. 9, no. 1, pp. 96–105, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Fishbane, W. Shapiro, P. Dutka, O. F. Valenzuela, and J. Faubert, “A randomized trial of iron deficiency testing strategies in hemodialysis patients,” Kidney International, vol. 60, no. 6, pp. 2406–2411, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. Wood, “Diagnosis and management of transfusion iron overload: the role of imaging,” American Journal of Hematology, vol. 82, supplement 12, pp. 1132–1135, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Stancu, A. Stanciu, A. Zugravu et al., “Bone marrow iron, iron indices, and the response to intravenous iron in patients with non—dialysis-dependent CKD,” American Journal of Kidney Diseases, vol. 55, no. 4, pp. 639–647, 2013. View at Publisher · View at Google Scholar
  26. R. Fischer and P. R. Harmatz, “Non-invasive assessment of tissue iron overload,” Hematology American Society of Hematology. Education Program, pp. 215–221, 2009. View at Google Scholar · View at Scopus
  27. P. Ferrari, H. Kulkarni, S. Dheda et al., “Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease,” Clinical Journal of the American Society of Nephrology, vol. 6, no. 1, pp. 77–83, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Rostoker, M. Griuncelli, C. Loridon et al., “Reassessment of iron biomarkers for prediction of dialysis iron overload: an MRI study,” PLoS ONE, vol. 10, no. 7, Article ID e0132006, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. T. G. St. Pierre, A. El-Beshlawy, M. Elalfy et al., “Multicenter validation of spin-density projection-assisted R2-MRI for the noninvasive measurement of liver iron concentration,” Magnetic Resonance in Medicine, vol. 71, no. 6, pp. 2215–2223, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Moirand, A. M. Mortaji, O. Loréal, F. Paillard, P. Brissot, and Y. Deugnier, “A new syndrome of liver iron overload with normal transferrin saturation,” The Lancet, vol. 349, no. 9045, pp. 95–97, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Brudevold, T. Hole, and J. Hammerstrøm, “Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload,” PLoS ONE, vol. 3, no. 10, Article ID e3547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. McDonald, “Incidence and treatment of esrd among indigenous peoples of australasia,” Clinical Nephrology, vol. 74, no. 1, pp. S28–S31, 2010. View at Google Scholar · View at Scopus
  33. K. O'Dea, J. Cunningham, L. Maple-Brown et al., “Diabetes and cardiovascular risk factors in urban Indigenous adults: results from the DRUID study,” Diabetes Research and Clinical Practice, vol. 80, no. 3, pp. 483–489, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. K. O'Dea, R. J. Lion, A. Lee, K. Traianedes, J. L. Hopper, and C. Rae, “Diabetes, hyperinsulinemia, and hyperlipidemia in small aboriginal community in northern Australia,” Diabetes Care, vol. 13, no. 8, pp. 830–835, 1990. View at Publisher · View at Google Scholar · View at Scopus
  35. Y. Hamada and M. Fukagawa, “Is hepcidin the star player in iron metabolism in chronic kidney disease,” Kidney International, vol. 75, no. 9, pp. 873–874, 2009. View at Publisher · View at Google Scholar · View at Scopus